Drug Trial Radar · NCT07573176
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Apr 30, 2026
Primary completion
Aug 24, 2028
Study completion May 3, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- May 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder (\[MDD\], a common mood disorder that causes a lasting feeling of sadness and a loss of interest in everyday activities) in double-blind treatment phase. Further, to evaluate long-term safety and tolerability of JNJ-42847922 in participants with MDD in the open label treatment phase.
Conditions
- Depressive Disorder, Major
Interventions
SeltorexantDrug
Seltorexant tablet will be administered orally.
PlaceboDrug
Placebo tablet will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double Blind (DB) Treatment Phase: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score in Participants with Major Depressive Disorder with Moderate-to-Severe Insomnia Symptoms (MDDIS)Time frame: Baseline up to Day 43
- Open-Label (OL) Treatment Phase: Number of Participants with Adverse Events Including Adverse Event of Special Interests (AESIs)Time frame: OL Baseline (Day 43) Up to 6 months
- OL Treatment Phase: Number of Participants with Vital Signs AbnormalitiesTime frame: OL Baseline (Day 43) Up to 6 months
- OL Treatment Phase: Number of Participants with Suicidality Assessment using Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: OL Baseline (Day 43) Up to 6 months
- OL Treatment Phase: Number of Participants with Withdrawal Symptoms Assessment Using Physician Withdrawal Checklist (PWC-20)Time frame: End of Treatment/Early withdrawal to end of the Follow-up visit (up to 14 days)
- OL Treatment Phase: Number of Participants with Abnormalities in Electrocardiogram (ECG)Time frame: OL Baseline (Day 43) up to 6 months
- OL Treatment Phase: Number of Participants Reporting Sexual Functioning using Arizona Sexual Experiences Scale (ASEX)Time frame: Up to 6 months
- OL Treatment Phase: Change from Baseline in the Body WeightTime frame: OL Baseline (Day 43) up to 6 months
- OL Treatment Phase: Change from Baseline in the Body Mass Index (BMI)Time frame: OL Baseline (Day 43) up to 6 months
- OL Treatment Phase: Change from Baseline in the Waist CircumferenceTime frame: OL Baseline (Day 43) up to 6 months
- OL Treatment Phase: Number of Participants with Abnormalities in Clinical Laboratory ParametersTime frame: OL Baseline (Day 43) up to 6 months
Locations
53 sites in 7 countries. Site status is shown where the registry gives one.
SanRo Clinical Research Group LLC WCG Clinical Network
Bryant, Arkansas · Recruiting
CI Trials
Bellflower, California · Recruiting
Behavioral Research Specialists LLC
Glendale, California · Recruiting
Excell Research Inc
Oceanside, California · Recruiting
NRC Research Institute
Orange, California · Recruiting
Cenexel
Riverside, California · Recruiting
Sunwise Clinical Research
Walnut Creek, California · Recruiting
UHC Research
Doral, Florida · Recruiting
Reliable Clinical Research
Hialeah, Florida · Recruiting
K2 Medical Research
Maitland, Florida · Recruiting
Pharmax Research Clinic Inc
Miami, Florida · Recruiting
Nuovida Research Center
Miami, Florida · Recruiting
IPTB Clinical Research
Tampa, Florida · Recruiting
Health Synergy Clinical Research
West Palm Beach, Florida · Recruiting
Agile Clinical Research Trials, LLC
Atlanta, Georgia · Recruiting
Accelerated Clinical Research Group LLC
Snellville, Georgia · Recruiting
Chicago Research Center
Chicago, Illinois · Recruiting
Pharmasite Research, Inc.
Baltimore, Maryland · Recruiting
Adams Clinical Boston
Boston, Massachusetts · Recruiting
Adams Clinical Watertown
Watertown, Massachusetts · Recruiting
Integrative Clinical Trials LLC
Brooklyn, Mississippi · Recruiting
SPRI Clinical Trials, LLC
Brooklyn, Mississippi · Recruiting
Vector Clinical Trials
Las Vegas, Nevada · Recruiting
CenExel Marlton NJ
Marlton, New Jersey · Recruiting
Bioscience Research LLC
Mount Kisco, New York · Recruiting
Fieve Clinical Research Inc
New York, New York · Recruiting
Adams Clinical Harlem
New York, New York · Recruiting
Manhattan Behavioral Medicine
New York, New York · Recruiting
Magnolia Clinical Research LLC
Cary, North Carolina · Recruiting
Patient Priority Clinical Sites LLC
Cincinnati, Ohio · Recruiting
Conrad Clinical Research
Edmond, Oklahoma · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
Future Search Trials of Dallas
Dallas, Texas · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
DM Clinical Research
Houston, Texas · Recruiting
Sooner Clinical Research
Oklahoma, Texas · Recruiting
R and H Clinical Research
Stafford, Texas · Recruiting
Alpine Research Organization
Clinton, Utah · Recruiting
Northwest Clinical Research Center
Bellevue, Washington · Recruiting
Iternova Consultorios en Salud Mental
Córdoba, Argentina · Recruiting
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.